Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors

6 Sept 2019

Abstract excerpt

The cyclin-dependent kinase 4/6 (CDK4/6) kinase is dysregulated in melanoma, highlighting it as a potential therapeutic target. CDK4/6 inhibitors are being evaluated in trials for melanoma and additional cancers. While beneficial, resistance to therapy is a concern, and the molecular mechanisms of such resistance remain undefined. We demonstrate that reactivation of mammalian target of rapamycin 1 (mTORC1)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31555743
DOI: 10.1126/sciadv.aax6352

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitorsPMID 31555743Read ↗

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21Semantic proximity Read ↗

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSemantic proximity Read ↗

Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers.Semantic proximity Read ↗

Adaptive post-transcriptional reprogramming of metabolism limits response to targeted therapy in BRAF <sup>V600</sup> melanomaSemantic proximity Read ↗

Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress.Semantic proximity Read ↗

Mitochondrial Signatures Shape Phenotype Switching and Apoptosis in Response to PLK1 and RSK Inhibitors in MelanomaSemantic proximity Read ↗

Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.Semantic proximity Read ↗

CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cellsSemantic proximity Read ↗

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma.Semantic proximity Read ↗

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical PracticeSemantic proximity Read ↗

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in CancerSemantic proximity Read ↗

CDK4 and CDK6 kinases: From basic science to cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.